one hundred nineteen patients with adenocarcinoma or large cell carcinoma were randomized to receive cyclophosphamide , adriamycin , cisplatin and mitomycin c ( capm ) or mitomycin c , cytosine arabinoside and tegafur ( mct ) , and 48 patients with squamous cell carcinoma were randomized to receive cisplatin , adriamycin and peplomycin ( pap ) or mitomycin c , cyclophosphamide , tespamine , toyomycin and tegafur ( mcttt ) .
C0001418
adenocarcinoma
C0002475
mitomycin c